Sutro Biopharma Inc
STRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.09M
Close$
$-0.82
107.1% downside
Current Fair Value
107.1% downsideOvervalued by 107.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138.09 Million |
|---|---|
| Enterprise Value | $101.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.49 |
| Beta | 1.5 |
| Outstanding Shares | 16,571,602 |
Return
| Return on Equity | 174.84% |
|---|---|
| Return on Assets | -92.89% |
| Return on Invested Capital | -99.21% |
Valuation & Multiples
| P/E Ratio | -0.82 |
|---|---|
| PEG | -0.35 |
| Price to Sales | 5.73 |
| Price to Book Ratio | -1.64 |
| Enterprise Value to Revenue | 2.21 |
| Enterprise Value to EBIT | -0.72 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-2.19
Average shareholder expectationRevenue Estimate
$11.96 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.66
Average shareholder expectationRevenue Estimate
$13.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9910▲ 99.10% |
|---|---|
| Total Calls | 11,100▲ Infinity% |
| Total Puts | 11,000▼ 82.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.75%▼ 8.00% |
|---|---|
| Total Invested | $547.31M▲ 55.88% |
| Investors Holding | 101▲ 29.00% |
ESG Score
No data
About Sutro Biopharma Inc
CEO: William Newell